Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰb/Ⅱ Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R09b in Patients With Parkinson's Disease

NCT06480461 is registered in ClinicalTrials.gov with Shanghai Vitalgen BioPharma Co., Ltd. as lead sponsor.

NCT NCT06480461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06480461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰb/Ⅱ Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R09b in Patients With Parkinson's Disease
Lead sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 2, 2024
Completion date
September 10, 2030
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease